Investing.com - Fate Therapeutics (NASDAQ: FATE) reported third quarter EPS of $-0.46, $0.10 better than the analyst estimate of $-0.56. Revenue for the quarter came in at $1.94M versus the consensus estimate of $1.59M.
Fate Therapeutics's stock price closed at $2.33. It is down -24.60% in the last 3 months and down -87.65% in the last 12 months.
Fate Therapeutics saw 6 positive EPS revisions and 9 negative EPS revisions in the last 90 days. See Fate Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Fate Therapeutics's Financial Health score is "fair performance".
Check out Fate Therapeutics's recent earnings performance, and Fate Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar